Abstract
New, target specific, oral anticoagulants have been shown to be safe and effective in prevention and treatment of thromboembolism without laboratory monitoring. However, clinical use of the drugs dabigatran, rivaroxaban, and apixaban requires laboratory measurement of their anticoagulant effect in specific clinical situations. This paper reviews the data available on use of screening and specialized testing to measure the anticoagulant effect and drug levels in patients prescribed these medications. Their effect on other coagulation assays is also reviewed.
Similar content being viewed by others
References
Garcia D, Libby E, Crowther MA (2010) The new oral anticoagulants. Blood 115:15–20
Davie EW, Ratnoff OD (1964) Waterfall sequence for intrinsic blood clotting. Science 145:1310–1312
Hoffman M, Monroe DM (2007) Coagulation 2006: a modern view of hemostasis. Hematol Oncol Clin North Am 21:1–11
Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G (2005) Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor—after multiple dosing in healthy male subjects. Clin Pharmacol Ther 78:412–421
Raghavean N, Frost CE, Yu Z et al (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37:74–81
Stangier J, Rathgen K, Stahle H, Gansser D, Roth W (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in male subjects. Br J Clin Pharmacol 64:292–303
Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E (2010) Assessment of laboratory assays to measure rivaroxaban—an oral, direct factor Xa inhibitor. Thromb Haemost 103:815–825
Hillarp A, Baghaei F, Blixter IF et al (2011) Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 9:133–139
Baglin T, Keeling D, Kitchen S (2012) Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standard in Haematology. Br J Haematol 159:427–429
Lindahl TL, Baghaei F, Blixter IF et al (2011) Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 105:371–378
van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A (2010) Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103:1116–1127
Love JE, Ferrell C, Chandler WL (2007) Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost 98:234–242
Stangier J, Feuring M (2012) Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 23:138–143
Nowak G (2004) The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb 33:173–183
Pengo V, Crippa L, Falanga A et al (2011) Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 106:868–876
Barrett YC, Wang ZQ, Frost C, Shenker A (2010) Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 104:1263–1271
Samama MM, Contant G, Spiro TE et al (2012) Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 107:379–387
Harenberg J, Marx S, Weiss C, Kramer R, Samama M, Schulman S (2012) Report of the subcommittee of control of anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost 10:1433–1436
Korte W, Jovic R, Hollenstein M, Degiacomi P, Gautschi M, Ferrandez A (2010) The uncalibrated prothrombinase-induced clotting time test. Equally convenient but more precise than the aPTT for monitoring of unfractionated heparin. Hamostaseologie 30:212–216
Harenberg J, Kraemer S, Du S, Giese C, Kraemer R (2012) Point of care method for the determination of dabigatran in urine samples from patients on treatment. American Society of Hematology Meeting Abstract #2270, San Diego
Funk DMA (2012) Coagulation assays and anticoagulant monitoring. Hematology 2012:460–465
Tichelaar V, de Jong H, Nijland H, Kluin-Nelemans H, Meijer K, Mulder A (2011) Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays. Thromb Haemost 106:990–992
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Konkle, B.A. Monitoring target specific anticoagulants. J Thromb Thrombolysis 35, 387–390 (2013). https://doi.org/10.1007/s11239-013-0880-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-013-0880-5